Research Grant on Antibody Drug Conjugates

Sponsor Deadline: 

May 1, 2023


Lung Cancer Research Foundation

UI Contact: 

2023 LCRF-Daiichi Sankyo- AstraZeneca Research Grant on Antibody Drug Conjugates

See complete details about this grant (pdf)

LCRF research grant programs fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, and other research.

2023 LCRF research grants will provide $270,000 over a period of two years for projects focused on one or more of the following topics that support research studies to develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs, including:

  • Employ state-of-the art technology to characterize ADC target expression on patient biopsies
  • Development and evaluation of patient-derived xenograft models (PDX) from patients responsive and/or resistant to TROP2 directed or HER2 directed ADCs
  • Discovery and/or validation of predictive biomarkers of TROP2 directed or HER2 directed ADCs efficacy in the lung cancer
  • Prevalence of potential prognostic or predictive biomarkers from lung cancer cells and/or blood
  • Co-expression of the identified biomarkers with other known biomarkers (eg actionable drivers, immune-related biomarkers, poor prognosis biomarkers)
  • Evolution of the biomarkers pre-, during- and post-SOC treatment